Egbert F Smit

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
    E F Smit
    Department of Pulmonary Diseases, Vrije University Medical Center, Amsterdam, The Netherlands
    Ann Oncol 23:1723-9. 2012
  2. doi request reprint A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
    Egbert F Smit
    Netherlands Cancer Institute, Thoracic Oncology, Amsterdam, The Netherlands Electronic address
    Lung Cancer 99:94-101. 2016
  3. doi request reprint Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study
    Egbert Smit
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Electronic address
    Lung Cancer 92:35-40. 2016
  4. pmc VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
    J L Kuiper
    Department of Pulmonary Diseases, VU University Medical Center, P O Box 7057, Amsterdam 1007 MB, The Netherlands
    Br J Cancer 107:1820-5. 2012
  5. pmc Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
    E C J Phernambucq
    Department of Pulmonary Diseases, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Br J Cancer 95:470-4. 2006
  6. doi request reprint Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
    Egbert F Smit
    Department of Pulmonary Diseases, Vrije Universiteit Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    J Clin Oncol 27:2038-45. 2009
  7. doi request reprint A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer
    Joline S W Lind
    Departments of Pulmonary Diseases, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    Clin Cancer Res 16:3078-87. 2010
  8. ncbi request reprint Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
    Corneline J Hoekstra
    Department of Nuclear Medicine, Vrije University Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 23:8362-70. 2005
  9. doi request reprint KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value
    Wouter W Mellema
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 8:1190-5. 2013
  10. doi request reprint DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer
    Robert A A van Boerdonk
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Thorax 69:451-7. 2014

Detail Information

Publications90

  1. doi request reprint Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
    E F Smit
    Department of Pulmonary Diseases, Vrije University Medical Center, Amsterdam, The Netherlands
    Ann Oncol 23:1723-9. 2012
    ....
  2. doi request reprint A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
    Egbert F Smit
    Netherlands Cancer Institute, Thoracic Oncology, Amsterdam, The Netherlands Electronic address
    Lung Cancer 99:94-101. 2016
    ..The CurrentS study (NCT01183858) assessed efficacy and safety of 300mg erlotinib (E300) as second-line therapy in current smokers with locally advanced or metastatic NSCLC versus the standard 150mg dose (E150)...
  3. doi request reprint Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study
    Egbert Smit
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Electronic address
    Lung Cancer 92:35-40. 2016
    ..Additionally, overall survival (OS) for patients who received cisplatin or carboplatin was evaluated...
  4. pmc VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
    J L Kuiper
    Department of Pulmonary Diseases, VU University Medical Center, P O Box 7057, Amsterdam 1007 MB, The Netherlands
    Br J Cancer 107:1820-5. 2012
    ....
  5. pmc Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
    E C J Phernambucq
    Department of Pulmonary Diseases, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Br J Cancer 95:470-4. 2006
    ..Median survival for all patients was 18 months. Response rate of accelerated cisplatin and high-dose epirubicin as induction chemotherapy for stage IIIa-N2 NSCLC patients is not different from more commonly used cisplatin-based regimen...
  6. doi request reprint Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
    Egbert F Smit
    Department of Pulmonary Diseases, Vrije Universiteit Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    J Clin Oncol 27:2038-45. 2009
    ..We performed a randomized phase II trial comparing pemetrexed with pemetrexed plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy...
  7. doi request reprint A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer
    Joline S W Lind
    Departments of Pulmonary Diseases, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    Clin Cancer Res 16:3078-87. 2010
    ....
  8. ncbi request reprint Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
    Corneline J Hoekstra
    Department of Nuclear Medicine, Vrije University Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 23:8362-70. 2005
    ....
  9. doi request reprint KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value
    Wouter W Mellema
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 8:1190-5. 2013
    ..The role of KRAS mutation as a predictor of response to chemotherapy for patients with metastatic NSCLC is poorly understood...
  10. doi request reprint DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer
    Robert A A van Boerdonk
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Thorax 69:451-7. 2014
    ..This classifier could assist in selecting subjects with endobronchial lesions who might benefit from more aggressive therapeutic intervention or surveillance. ..
  11. pmc Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography
    Virginie Frings
    Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
    PLoS ONE 8:e63705. 2013
    ..The aim of this study was to investigate the effect of pemetrexed-induced TS-inhibition on ¹⁸F-FLT uptake 4 hours after pemetrexed administration in metastatic NSCLC patients...
  12. ncbi request reprint Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study
    Klaartje W Maas
    Department of Pulmonary Diseases, St Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
    Anticancer Res 30:4237-43. 2010
    ..This prospective study analyzed the feasibility and efficacy of weekly concurrent chemoradiation (docetaxel/cisplatin) followed by surgery. The primary endpoint was radiological response...
  13. pmc Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    PLoS ONE 3:e0001722. 2008
    ..Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease...
  14. doi request reprint Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status
    Idris Bahce
    Departments of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands
    Clin Cancer Res 19:183-93. 2013
    ....
  15. doi request reprint Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Cell 21:82-91. 2012
    ..These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs...
  16. ncbi request reprint Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project
    Remco M van den Berg
    Department of Pulmonary Diseases, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Int J Oncol 37:455-61. 2010
    ..hTERT mRNA level in tumour tissue has no prognostic value for patients with early stage lung cancer. However, detection of hTERT mRNA expression in tumour-distant normal lung tissue may indicate an increased risk of progressive disease...
  17. doi request reprint Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patients
    Barbara S van der Meij
    Department of Nutrition and Dietetics, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 6:1563-8. 2011
    ..The aim of this retrospective study was to investigate the predictive value of nutritional parameters on postoperative morbidity, mortality, and survival...
  18. doi request reprint Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 51:1684-90. 2010
    ..The purpose of the present study was to assess validity and reproducibility of dynamic H(2)(15)O PET/CT scans for measuring tumor perfusion and validate the quantitative accuracy of parametric perfusion images...
  19. pmc Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis
    Roderick H J Breuer
    Department of Pathology, VU Medical Center, Amsterdam, The Netherlands
    Neoplasia 6:736-43. 2004
    ..Because PcG complexes are normally involved in the maintenance of cell characteristics, abnormal PcG expression may contribute to loss of cell identity...
  20. pmc Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    Eur Radiol 20:2890-8. 2010
    ....
  21. doi request reprint Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 17:4814-24. 2011
    ..The secondary objective was to investigate whether [(11)C]docetaxel kinetics were associated with tumor perfusion, tumor size, and dexamethasone administration...
  22. doi request reprint Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 74:1391-6. 2009
    ..The present dose-escalation Phase I trial evaluated the toxicity of whole brain radiotherapy (WBRT) with concurrent and maintenance erlotinib in this patient group...
  23. doi request reprint Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
    Eline E Verwer
    Department of Radiology and Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 40:1523-31. 2013
    ..The aims of this study were to determine the optimal kinetic model along with validation of using alternatives to arterial blood sampling for analysing [(18)F]FAZA studies and to assess the validity of simplified analytical methods...
  24. doi request reprint Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography
    Astrid A M van der Veldt
    Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 19:4163-73. 2013
    ..The objective of this study was to investigate whether a [(11)C]docetaxel PET microdosing study could predict tumor uptake of therapeutic doses of docetaxel...
  25. ncbi request reprint CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone
    Remco M van den Berg
    Department of Pulmonology, VU University Medical Center, Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Lung Cancer 60:57-61. 2008
    ..We performed a secondary analysis of CT data of subjects at risk of lung cancer enrolled in a chemoprevention trial of fluticasone...
  26. doi request reprint High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis
    Robert A A van Boerdonk
    Department of Pathology, Academic Center for Dentistry Amsterdam ACTA, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 8:711-8. 2013
    ..Since a causal contribution of hrHPV infection to lung cancer (LC) is still a matter of debate, a comprehensive study was performed to delineate hrHPV involvement in LC, using a Dutch study population...
  27. doi request reprint Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer
    Frank J Lagerwaard
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 83:348-53. 2012
    ..As an increasing number of fit patients have elected to undergo stereotactic ablative radiotherapy (SABR) in recent years, we studied outcomes after SABR in patients with potentially operable stage I NSCLC...
  28. doi request reprint Reproducibility of tumor perfusion measurements using 15O-labeled water and PET
    Adrianus J de Langen
    Department of Respiratory Medicine, VU University Medical Centre, Amsterdam, The Netherlands
    J Nucl Med 49:1763-8. 2008
    ..However, to use the technique for serial imaging of individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative H215O measurements...
  29. doi request reprint Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis
    Adrianus J de Langen
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 53:701-8. 2012
    ..Therefore, we determined the repeatability of different standardized uptake value (SUV) measurements using the available data...
  30. doi request reprint Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens
    Remco M van den Berg
    Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Lung Cancer 72:316-21. 2011
    ..Hence, CADM1 methylation analysis is unlikely to have diagnostic value for the early detection of lung cancer in an unselected population. However, a diagnostic value for selected subjects, such as females, cannot be excluded...
  31. doi request reprint Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 5:554-7. 2010
    ..Nevertheless, no reliable markers can differentiate an osteoblastic flare or response from disease progression. In non-small cell lung cancer (NSCLC) osteoblastic bone flare or response has been reported in only a few patients...
  32. pmc Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
    Floris H P van Velden
    Department of Nuclear Medicine and PET Research, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 38:1636-47. 2011
    ..The purpose of this study was therefore to implement and characterize a method that enables quantification of heterogeneity in tumour FDG uptake...
  33. doi request reprint Fatal interstitial lung disease after erlotinib for non-small cell lung cancer
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 3:1050-3. 2008
    ..The sparse data on the clinical presentation, radiographic patterns, and histologic findings of epidermal growth factor receptor tyrosine kinase inhibitor-associated interstitial lung disease are discussed...
  34. doi request reprint Critical review of nonsurgical treatment options for stage I non-small cell lung cancer
    Cornelis J A Haasbeek
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Oncologist 13:309-19. 2008
    ..Reported 2-year local control rates after SRT are comparable with those achieved with surgery, and prospective randomized trials comparing surgery with SRT in patients who are fit to undergo surgery are now being planned...
  35. doi request reprint Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer
    Erik C J Phernambucq
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Lung Cancer 74:451-6. 2011
    ..03). Limiting lung doses to ≤30Gy during CCRT may limit sub-clinical damage, and the time-course of RLD changes may allow for early quantification of pulmonary damage when evaluating novel treatment strategies...
  36. doi request reprint Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer
    Virginie Frings
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands
    J Nucl Med 51:1870-7. 2010
    ....
  37. doi request reprint Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
    Markus Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer 118:2466-75. 2012
    ..The authors assessed the impact of germline polymorphisms on clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC) who received platinum-gemcitabine (PG) chemotherapy...
  38. ncbi request reprint Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET
    Corneline J Hoekstra
    Clinical PET Centre, VU University Medical Centre, Amsterdam, The Netherlands
    J Nucl Med 43:1304-9. 2002
    ..The aim of this study was to select those methods that would qualify for further assessment in a future prospective response-monitoring study by comparing results with patient outcome...
  39. doi request reprint Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 4:1585-6. 2009
    ..Our case suggests that in the presence of rash, dose reductions to "subtherapeutic" levels remain effective and may prevent unnecessary early treatment termination...
  40. ncbi request reprint Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
    Egbert F Smit
    Department of Pulmonogy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 21:3909-17. 2003
    ....
  41. doi request reprint Quantitative and Simplified Analysis of 11C-Erlotinib Studies
    Maqsood Yaqub
    Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 57:861-6. 2016
    ..The purpose of this study was to find the optimal pharmacokinetic model for quantification of uptake and to evaluate various simplified methods for routine analysis of (11)C-erlotinib uptake in NSCLC patients...
  42. doi request reprint EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study
    A Jasmijn Hubers
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Lung Cancer 82:38-43. 2013
    ..The aim of the present study was to determine whether EGFR mutation analysis is attainable on sputum samples, employing different assays in a multicenter study...
  43. doi request reprint Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI
    Adrianus J de Langen
    Department of Pulmonary Diseases, VU University Medical Center, and Department of Biostatistics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Nucl Med 52:48-55. 2011
    ..The present study assessed the predictive value of molecular imaging for the identification of survival benefit during antiangiogenic treatment with bevacizumab and erlotinib in patients with advanced non-small cell lung cancer...
  44. pmc The use of erlotinib in daily practice: a study on adherence and patients' experiences
    Lonneke Timmers
    Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    BMC Cancer 11:284. 2011
    ....
  45. ncbi request reprint Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study
    Gerarda J M Herder
    Department of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 24:1800-6. 2006
    ..We investigated whether application of positron emission tomography (PET) immediately after first presentation might simplify staging while maintaining accuracy, as compared with traditional strategy in routine clinical setting...
  46. pmc Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease
    Maria J Overbeek
    Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Arthritis Res Ther 13:R61. 2011
    ..Immunoreactivity patterns of phosphorylated PDGFR-β (pPDGFR-β) and the ligand PDGF-B were evaluated to provide more insight into the patterns of PDGFR-b activation...
  47. ncbi request reprint The natural course of preneoplastic lesions in bronchial epithelium
    Roderick H Breuer
    Department of Pulmonology, Vrije Universiteit Medical Center, 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 11:537-43. 2005
    ..To study the natural history of preneoplastic lesions in the bronchial mucosa of the individuals at risk...
  48. ncbi request reprint The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium
    Remco M van den Berg
    Department of Pulmonology, VU Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Am J Respir Crit Care Med 175:1061-5. 2007
    ..Bronchial epithelium exposed to cigarette smoke undergoes a series of histologic changes that may ultimately lead to invasive cancer. Inhaled corticosteroids reduce the number of lung tumors developing in rats exposed to cigarette smoke...
  49. doi request reprint DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer
    Robert A A van Boerdonk
    VU University Medical Center, Department of Pathology, De Boelelaan 1117, Amsterdam, The Netherlands
    Am J Respir Crit Care Med 184:948-56. 2011
    ..Autofluorescence bronchoscopy (AFB) is a valid strategy for detecting premalignant endobronchial lesions. However, no biomarker can reliably predict lung cancer risk of subjects with AFB-visualized premalignant lesions...
  50. doi request reprint Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography
    Adrianus J de Langen
    Department of Respiratory Medicine, VU University Medical Centre, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:389-95. 2009
    ..For serial imaging in individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative [(18)F]FLT measurements...
  51. doi request reprint Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands
    Cancer 117:597-605. 2011
    ..The authors aimed to identify patient groups with synchronous BM for whom radical treatment of the primary site may be appropriate...
  52. doi request reprint Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer
    A Jasmijn Hubers
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    J Clin Pathol 65:541-5. 2012
    ..The aim of this methodological study was to determine whether the hypermethylation detection rate of RASSF1A, adenomatous polyposis coli (APC) and cytoglobin (CYGB) is influenced by the duration of sputum collection...
  53. doi request reprint Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer
    Erik C J Phernambucq
    Department of Pulmonary Diseases, VU University Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Cardiothorac Surg 36:1052-7. 2009
    ..We describe the outcome of a treatment strategy to limit the duration of treatment splits...
  54. doi request reprint Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer
    Annemarie Becker
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 5:1477-80. 2010
    ..Patients with a mutation or deletion in the epidermal growth factor receptor gene will benefit most and are likely to receive the drug for long periods and willing to accept side effects if responding...
  55. doi request reprint Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013
    Chris Dickhoff
    Department of Cardio Thoracic Surgery, VU University Medical Center, Amsterdam, the Netherlands Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands Electronic address
    J Thorac Oncol 11:566-72. 2016
    ..We explored the use of operations for cIIIA NSCLC in the Netherlands...
  56. doi request reprint Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib
    Vivian E M van den Boogaart
    Department of Pulmonary Diseases, VieCuri Medical Center, Tegelseweg 210, 5912 BL Venlo, The Netherlands Department of pulmonary diseases, Maastricht University Medical Center, P O Box 5800, 6202 AZ Maastricht, The Netherlands Electronic address
    Lung Cancer 93:20-7. 2016
    ..Therefore we have evaluated the inter-reader reproducibility of response classification by DCE-MRI in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab and erlotinib enrolled in a multicenter trial...
  57. pmc Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
    Idris Bahce
    Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007MB, Amsterdam, The Netherlands
    EJNMMI Res 6:10. 2016
    ....
  58. doi request reprint Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery
    Gwendolyn H M J Griffioen
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Radiother Oncol 107:403-8. 2013
    ..Current guidelines recommend a curative approach when early-stage MPLC is diagnosed as favorable outcomes have been reported after surgery. We studied outcomes following stereotactic ablative radiotherapy (SABR)...
  59. ncbi request reprint Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer
    Godefridus J Peters
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Anticancer Res 34:435-42. 2014
    ..In currently ongoing and future prospective studies, patients should be selected based on their DNA repair status, but it still has to be determined whether this should be by immunohistochemistry, mRNA expression, or a polymorphism. ..
  60. ncbi request reprint A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:3642-51. 2007
    ..To establish maximum tolerated dose (MTD) and tolerability of two schedules of bortezomib in combination with cisplatin and gemcitabine as first-line treatment of patients with advanced solid tumors...
  61. pmc Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:1950-8. 2010
    ..The purpose of the present study was to determine the biodistribution and radiation absorbed dose of [(11)C]docetaxel in humans...
  62. doi request reprint Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010
    Ellen J F van Reij
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Acta Oncol 53:316-23. 2014
    ..We assessed the response to national guidelines introduced in 2004 and the impact on outcomes...
  63. doi request reprint Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer
    Virginie Frings
    Department of Radiology and Nuclear Medicine, VU University Medical Center VUmc, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Mol Imaging Biol 16:136-45. 2014
    ..To investigate the effect of image-derived input functions (IDIF), input function corrections and volume of interest (VOI) size in quantification of [(18)F]FLT uptake in non-small cell lung cancer (NSCLC) patients...
  64. doi request reprint Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks
    Barbara S van der Meij
    Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Br J Nutr 109:2231-9. 2013
    ..Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients...
  65. doi request reprint Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer
    Terry G Wiersma
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Lung Cancer 80:62-7. 2013
    ..We analyzed toxicity and survival outcomes for patients undergoing CRT with a planning target volume (PTV) exceeding 700 cc, either with or without N3 nodal disease, or a PTV less then 700 cc with N3 disease...
  66. doi request reprint Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus
    Johannes L Blaauwgeers
    Department of Pathology, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1090, hm, Amsterdam, The Netherlands
    Virchows Arch 462:547-56. 2013
    ..A modification of the pathological staging system after radiotherapy, incorporating the percentage of vital tumour cells, is proposed...
  67. doi request reprint Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma
    Erik Thunnissen
    Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Virchows Arch 461:629-38. 2012
    ..In the diagnostic work-up of non-small cell lung carcinoma the limited reproducibility on small biopsies is optimized with immunohistochemical analysis, resulting in reliable delineation for predictive analysis...
  68. doi request reprint Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    Elisa Giovannetti
    Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam CCA 1 52, Amsterdam, The Netherlands
    Mol Cancer Ther 9:581-93. 2010
    ....
  69. pmc Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis
    Patsuree Cheebsumon
    Department of Nuclear Medicine and PET Research, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 38:832-42. 2011
    ..The goal of this study was to analyse and compare various semi-quantitative measures for response assessment with full kinetic analysis, specifically in assessment of novel therapies...
  70. doi request reprint Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment
    Barbara S van der Meij
    Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
    J Nutr 140:1774-80. 2010
    ..03 and B = 25.0 g, P = 0.01, respectively). In conclusion, a protein- and energy-dense oral nutritional supplement containing (n-3) fatty acids beneficially affects nutritional status during multimodality treatment in patients with NSCLC...
  71. doi request reprint Second primary lung cancers following a diagnosis of primary head and neck cancer
    Gwendolyn H M J Griffioen
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands Electronic address
    Lung Cancer 88:94-9. 2015
    ..We reviewed our institutional experience on the treatment and prognosis of SPLC patients, both at the time of diagnosis, and following treatment of HNSCC, in order to explore treatment outcomes...
  72. ncbi request reprint Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer
    Klaartje W Maas
    Department of Pulmonary Diseases, St Antonius Hospital, Nieuwegein, The Netherlands
    Curr Opin Pulm Med 13:297-304. 2007
    ..Although the role of surgical resection in combined modality treatment is unclear, surgery will be discussed as a potential part of the treatment approach...
  73. ncbi request reprint Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer
    Mikael E Craanen
    Department of Gastroenterology, VU University Medical Center, P O Box 7057, 1007MB, Amsterdam, The Netherlands
    Interact Cardiovasc Thorac Surg 6:433-6. 2007
    ..However, initial (18)FDG-PET findings should guide the complementary use of EUS-FNA to define treatment options and to prevent unnecessary surgery in selected patients...
  74. pmc Scheduling of anticancer drugs: timing may be everything
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Cell Cycle 11:4339-43. 2012
    ..Positron emission tomography (PET) using radiolabeled anticancer drugs could be an important tool for those studies...
  75. pmc Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial
    Anne Marie H Krebber
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 12:173. 2012
    ..A stepped care approach has the potential to improve the efficiency of psychosocial care. The aim of the study described herein is to evaluate efficacy of a stepped care strategy targeting psychological distress in cancer survivors...
  76. doi request reprint KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA
    Daniëlle A M Heideman
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    J Mol Diagn 14:247-55. 2012
    ..HRM-SNaPshot is an attractive method for mutation analysis in pathology, given its good performance rate on FFPE-derived DNA, high analytical sensitivity, and prescreening approach...
  77. ncbi request reprint Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ)
    Peter J F Snijders
    Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Int J Cancer 109:412-7. 2004
    ..03). These data indicate that elevated hTERT mRNA is associated with an increased relative risk of prevalent and incident bronchial squamous cell carcinoma (in situ)...
  78. doi request reprint The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteers
    Romane M Schook
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 5:1240-5. 2010
    ..The aim of this study was to evaluate whether the participation on a chemoprevention study for premalignant lesions could influence smoking cessation...
  79. doi request reprint Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer
    Julien Vincenten
    Department of Pulmonology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    J Thorac Oncol 7:1522-7. 2012
    ..The aim of the current study is to evaluate the potential of NKX2-1 immunohistochemistry as a prescreening test for EGFR mutation analysis...
  80. ncbi request reprint The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules
    Gerarda J Herder
    Department of Pulmonary Diseases, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 31:1231-6. 2004
    ..Such results may help in the design of larger prospective trials with structured clinical work-up...
  81. doi request reprint Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review
    Mathilda L Bongers
    Department of Epidemiology and Biostatistics, VU Medical Centre, Amsterdam, The Netherlands
    Pharmacoeconomics 30:17-34. 2012
    ..We found indications of superiority in terms of cost effectiveness for gemcitabine+cisplatin in a first-line setting, and for erlotinib in a second-line setting...
  82. ncbi request reprint [Treatment and prognosis of superior sulcus tumours]
    C G Niels Vos
    VU Medisch Centrum, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 156:A5419. 2012
    ..Treatment of superior sulcus tumours requires a multidisciplinary approach; considering the complexity of the treatment, patients should be referred to a specialised centre...
  83. doi request reprint Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer
    Frank J Lagerwaard
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 70:685-92. 2008
    ..We evaluated early clinical outcomes of "risk-adapted" fractionation schemes in patients treated in a single institution...
  84. ncbi request reprint Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 2:12-21. 2007
    ..A better understanding of the molecular alterations present in the different lesions may help in defining this relation...
  85. pmc Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study
    Maria J Overbeek
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    Respir Res 9:68. 2008
    ..The use of the partitioned diffusion to detect PAH in SSc is not well established yet. This study evaluates whether Dm and Vc could be candidates for further study of the use for screening for PAH in SSc...
  86. ncbi request reprint [EGFR-mutation in non-small cell lung carcinoma. Treatment with tyrosine kinase inhibitors possible]
    Erik Thunnissen
    VU Medisch Centrum, afd Pathologie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 155:A2554. 2011
    ....
  87. doi request reprint Low molecular weight heparins in the treatment of lung cancer
    Wouter W Mellema
    VU Medical Center, Pulmonology, Amsterdam, The Netherlands
    Expert Opin Investig Drugs 20:1517-22. 2011
    ..For prevention and treatment of VTE, low molecular weight heparins (LMWH) are superior to vitamin K antagonists. There is some evidence that LMWH may improve survival in cancer patients...
  88. ncbi request reprint Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography
    Corneline J Hoekstra
    Clinical PET Centre and Departments of Pulmonary Medicine, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 8:2109-15. 2002
    ..The objective of the present study was to assess whether it is feasible to measure perfusion in vivo in non-small cell lung cancer (NSCLC) using H(2)(15)O and positron emission tomography...
  89. ncbi request reprint Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer
    Roderick H J Breuer
    Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Lung Cancer 40:165-72. 2003
    ....
  90. pmc Angiogenesis inhibitors in the treatment of non-small cell lung cancer
    Joline S W Lind
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    Ther Adv Med Oncol 1:95-107. 2009
    ..However, a number of unresolved issues remain. In this review, we discuss the main angiogenesis inhibitors in development for the treatment of NSCLC focusing on the VEGF pathway...